2011 - ISBTS 2011 Symposium

This page contains exclusive content for the member of the following sections: TTS, ITA

Oral Communications 6: Surgical Aspects of ITX

8.152 - Surgical and transplant approach to complicated intestinal failure: Italian series 2000-2011 on adults

Presenter: Chiara, Zanfi, Bologna, Italy
Authors: Augusto Lauro1, Chiara Zanfi1, Sara Pellegrini1, Alessandro Dazzi1, Matteo Cescon1, Giorgio Ercolani1, Luca Ansaloni1, Giovanni Ramacciato1, Fausto Catena1, Loris Pironi1, Antonio Daniele Pinna1

Surgical and transplant approach to complicated intestinal failure: Italian series 2000-2011 on adults

Augusto Lauro, Chiara Zanfi, Sara Pellegrini, Alessandro Dazzi, Matteo Cescon, Giorgio Ercolani, Luca Ansaloni, Giovanni Ramacciato, Fausto Catena, Loris Pironi, Antonio Daniele Pinna

Liver and Multiorgan Transplant Center, S. Orsola Hospital, Bologna, Italy

Aim: We report our experience about surgical and transplant intestinal approach on adults with complicated intestinal failure.

Methods: Between 2000-2011, 93patients were evaluated for surgical bowel rehabilitation.

Forty-five (48,3%)underwent 46 transplantations (34 isolated, 12 multivisceral), due to SBS,Gardner's ,CIPO.

Forty-eight (51,7 %)underwent surgical rescue (due to fistulas, stenosis, SBS, complete portal thrombosis) with resection, adhesiolysis, stricturoplasty, OLTx with porto-caval hemitrasposition (5 patients-rescuing own bowel).

Results: Among transplant population (mean followup 1561 ± 1294 days) 22 (47.8%) are alive with 1-3-5-10 years patient survival of 77%, 58% , 53% ,37%; 1-3-5-10 years graft survival is 68%, 56 % , 51% ,35%.

Thirthy-two underwent Alemtuzumab induction(plus FK), 12 Daclizumab(plus FK-steroids) ,2 Thymoglobulin (plus FK): on 11 we applied new Alemtuzumab protocol, administering 15 mg each patient at day 0 and 7 , instead 4 doses -eight patients are alive.

Currently, 56% intestinal recipients and 25% multivisceral ones are alive: survival in alemtuzumab group after 3,5 ,7 years was 49%, 45% , 45% while in daclizumab one was 75% , 66% , 50% (P=0,56). Younger recipients (< 40 years at transplant) had  better survival (64% ,64% at 3, 5 years) compared to older ones ( 40% , 24% at 3 , 5 years) (P=0,01). Nutritional autonomy was achieved on all survivors (3 are on TPN also).

Regarding multivisceral transplants, all but 2 (deceased for infection) underwent splenectomy.

Among rescue population( mean followup 734 ± 707 days-nine patients were lost), 36patients (92%) are alive (3 died),78%is off TPN, 22%is on TPN plus oral feeding. One, 3 , 5 years survival is 94%,94% , 83%.

Conclusions: Survival decreases after intestinal transplantation: in our series half population is alive. Surgical rescue allows intestinal recovery with lower mortalityand morbidity.

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.



Staff Directory
This email address is being protected from spambots. You need JavaScript enabled to view it.


The Transplantation Society
International Headquarters
505 Boulevard René-Lévesque Ouest
Suite 1401
Montréal, QC, H2Z 1Y7